2022-10-21

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

ROI-NJ: BD’s new Onclarity HPV test greatly improves standard of care for women

Molly Broache, Associate Director, Medical Affairs for US IDS explains how the BD Onclarity™ HPV Assay positively impacts public health by providing a more precise estimate of a woman’s risk of cervical precancer and cancer.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

Molly Broache, Associate Director, Medical Affairs for US IDS discusses the future of cervical cancer screening
Cervical Cancer | News & Updates
Clinical Lab Products: The Future of Cervical Cancer Screening is Here
physician and patient
New Harris Poll Finds Women Want More Education on Sexually Transmitted Infections Testing and Treatment
ReachMD: The importance of extended genotyping in cervical cancer screening: The special case of HPV 31
Cervical Cancer | Webinars & Videos
ReachMD: The importance of extended genotyping in cervical cancer screening: The special case of HPV 31